Marinus Pharmaceuticals, Inc. (MRNS) Analysts See $-0.15 EPS

July 13, 2018 - By Nellie Frank

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) LogoInvestors sentiment decreased to 1.12 in 2018 Q1. Its down 0.88, from 2 in 2017Q4. It dived, as 12 investors sold Marinus Pharmaceuticals, Inc. shares while 14 reduced holdings. 14 funds opened positions while 15 raised stakes. 18.52 million shares or 9.78% less from 20.53 million shares in 2017Q4 were reported.
Quantbot Limited Partnership has 2,148 shares. Gmt Capital invested 0.12% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Daiwa Securities Inc reported 223 shares. 36,697 were accumulated by Retail Bank Of Ny Mellon. Shanda Asset Mngmt invested in 0.01% or 10,000 shares. Barclays Public Ltd Limited Liability Company owns 60,501 shares. Dekabank Deutsche Girozentrale holds 17,000 shares. One Trading Ltd Partnership invested 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Proshare Advisors Ltd Limited Liability Company accumulated 18,692 shares. Jpmorgan Chase & stated it has 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Art Advisors Ltd Liability Co holds 0.01% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 43,828 shares. Northern Corp has invested 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Bluecrest Mgmt Ltd reported 32,487 shares or 0% of all its holdings. 683 Mgmt invested 0.41% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Artal Grp, Luxembourg-based fund reported 500,000 shares.

Since January 29, 2018, it had 0 insider purchases, and 1 sale for $23,730 activity.

Analysts expect Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) to report $-0.15 EPS on August, 7.They anticipate $0.06 EPS change or 28.57 % from last quarter’s $-0.21 EPS. After having $-0.15 EPS previously, Marinus Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 2.38% or $0.19 during the last trading session, reaching $7.79. About 441,574 shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has risen 405.13% since July 13, 2017 and is uptrending. It has outperformed by 392.56% the S&P500.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Ratings Coverage

Among 4 analysts covering Marinus (NASDAQ:MRNS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Marinus had 4 analyst reports since March 19, 2018 according to SRatingsIntel. Robert W. Baird initiated the stock with “Buy” rating in Wednesday, May 23 report. Mizuho initiated Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) rating on Monday, March 19. Mizuho has “Buy” rating and $13.0 target.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $315.66 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

More notable recent Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) news were published by: Streetinsider.com which released: “Cantor Fitzgerald Starts Marinus Pharmaceuticals (MRNS) at Overweight” on July 02, 2018, also Fool.com with their article: “3 Soaring Biotech Stocks. Can They Keep Climbing?” published on June 21, 2018, Nasdaq.com published: “Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder” on June 19, 2018. More interesting news about Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) were released by: Globenewswire.com and their article: “Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)” published on June 15, 2018 as well as Nasdaq.com‘s news article titled: “Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index” with publication date: June 21, 2018.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>